Yazarlar : Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A.

Yayın : Blood.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21828141

Konu : Lenfoma

Literatür İçeriği :  

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for about 5% of Hodgkin lymphoma cases. The disease is characterized by a strong CD20 expression on the malignant cells and a more indolent clinical course as compared to classical HL (cHL). Anti-CD20 antibody treatment has shown clinical activity in relapsed NLPHL. In this phase II trial, we investigated rituximab in newly diagnosed stage IA NLPHL patients. Four weekly applications at 375 mg/m(2) were given. Among the 28 evaluable patients, overall response rate was 100%, 24 patients (85.7%) achieved complete remission and four (14.3%) partial remission. At a median follow-up of 43 months, overall survival was 100%; progression-free survival at 12, 24 and 36 months was 96.4%, 85.3% and 81.4%, respectively. No grade III/IV toxicity was observed. Although treatment results with rituximab appear inferior in comparison with radiotherapy and combined-modality approaches in early-stage patients, investigation of anti-CD20 antibody-based combinations in NLPHL is warranted. This study was registered at www.clinicaltrials.gov as NCT00346684.

Literatür Arşivi